Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Clearmind Medicine (CMND) has established a research and development partnership with the Yissum Research Development Company
  • The collaboration will focus on developing novel, innovative, patentable psychedelics
  • Researchers at The Hebrew University will investigate and innovate synthetic novel analogs of known psychedelic compounds
  • Yissum serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors and industry
  • Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems
  • Clearmind Medicine Inc. (CMND) opened trading at C$0.87 per share

Clearmind Medicine (CMND) has established a research and development partnership with the Yissum Research Development Company.

Yissum is the technology transfer company of The Hebrew University of Jerusalem. Yissum is known for its ability to discover, analyze and design advanced platforms for synthesizing various structurally related compounds as potential therapeutic agents and drug candidates.

The collaboration will focus on developing novel, innovative, patentable psychedelics as potential drug candidates to expand Clearmind’s IP portfolio.

According to the terms of the agreement, researchers at The Hebrew University will investigate and innovate synthetic novel analogs of known psychedelic compounds, conduct in silico 3D docking studies and rational design, and screen the compounds in an in vitro platform.

Adi Zuloff-Shani, Ph.D., CEO of Clearmind commented on the announcement.

“This is an important partnership for Clearmind. The academic/technology transfer model is responsible for many medical breakthroughs, and the Hebrew University-Yissum partnership is one of the most prolific in the field. I am certain that our collaboration will yield many potential candidates for further evaluation.”

Dr. Ilya Pittel, VP of business development at Yissum Research Development Company commented on the partnership.

“Yissum is looking forward to collaborating with Clearmind in its mission to discover novel psychedelic compounds. We have assigned our top researchers from multiple fields to this project, and I am confident their broad expertise and know-how will facilitate Clearmind’s ability to expand their pipeline portfolio.”

Professor Tsvelihovsky added,

“Professors Avi Priel and Masha Niv and I are excited to work with the team at Clearmind to create unique synthetic compounds for the development of novel GPCR-focused therapeutics. We believe psychedelics are going to revolutionize the treatment of mental health, and Clearmind’s plans put it on the leading edge of innovation in the field. We are quite optimistic that our efforts will lead to new psychotherapy drug candidates.”

Yissum serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors and industry.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems.

Clearmind Medicine Inc. (CMND) opened trading at C$0.87 per share.

More From The Market Herald
Small Pharma - CEO, Peter Rands.

" Small Pharma (TSXV:DMT) granted European patent

Small Pharma (DMT) has been granted a European patent, strengthening its ketamine-based patent portfolio.

" Levitee Labs (CSE:LVT) enters into credit facility for up to $12 Million

Levitee Labs Inc. (LVT) has entered into a financing agreement for up to $12 million to fund further business expansion.
Small Pharma - Chief Medical and Scientific Officer, Carol Routledge.

" Small Pharma (TSXV:DMT) granted fast-track designation for DMT-assisted therapy

Small Pharma (DMT) has been granted fast-track designation in the U.K. for DMT-assisted therapy for major depressive disorder.

" Psyched Wellness (CSE:PSYC) shares preliminary data from amanita muscaria mushroom study

Psyched Wellness Ltd. (PSYC) has released its preliminary data revealing a potential new functional property and health benefit of AME-1.